Physician profile
Benjamin A Solky
NPI 1932186772
$6,502.94
in general payments reported to CMS, 2019-2025
24 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $482 · 2021: $1,015 · 2022: $1,263 · 2023: $1,038 · 2024: $1,185 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,199.51 | 2019-2025 | Otezla, Otezla, Enbrel |
| Abbvie INC. | $1,143.88 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $590.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $582.34 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $544.40 | 2019-2025 | Simponi Aria, Stelara, Simponi |
| Leo Pharma INC. | $254.01 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $230.37 | 2021-2025 | Libtayo |
| Genentech USA, INC. | $221.26 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $217.56 | 2023-2025 | Ilumya |
| Celgene Corporation | $214.71 | 2019-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $208.65 | 2023-2025 | Zoryve |
| Ucb, INC. | $177.69 | 2020-2022 | |
| Incyte Corporation | $171.27 | 2021-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $152.46 | 2019-2022 | |
| Organon LLC | $140.58 | 2025 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $135.55 | 2024-2025 | |
| Galderma Laboratories, L.P. | $93.37 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.99 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $37.83 | 2023 | Idacio |
| Dermira, INC. | $37.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.04 | 2023 | Spevigo |
| Organogenesis INC. | $24.98 | 2023 | Puraply |
| Pfizer INC. | $18.62 | 2021 | |
| Almirall LLC | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Solky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.